How Should Labelling and Instructions for Use Be Localised for Medical Device Registration in the Philippines?

Answer: To localise labelling and instructions for use (IFU) for medical device registration in the Philippines, a manufacturer should first confirm the target country, the product's risk classification, the applicable regulatory pathway and the documentation already available. It should then assess the technical file, quality system evidence, labelling and IFU, the local agent or authorised representative arrangement, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete documentation or poorly defined authorisation arrangements do not extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change control at the same time. If the project is driven only by a list of documents to submit, deficiencies and rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate ownership. AIMEILI advises companies to plan this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, rather than rebuilding documentation from scratch for each country.

Compiled from AIMEILI's medical device international registration practice library and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the manufacturer's existing product documentation.

Overview

Article type: FAQ

Title: How should labelling and instructions for use be localised for medical device registration in the Philippines?

Published: 2026-07-10 19:29

Updated: 2026-07-10 19:29

This article reviews the questions companies should prioritise in actual projects concerning international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI's View
• Frequently Asked Follow-Up Questions
• Continued Reading
• Scope of Application

Key Summary

On the question of how to localise labelling and instructions for use for medical device registration in the Philippines, companies should first confirm the target country, the product's risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality system, labelling and IFU, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, to avoid extending the project timeline due to unclear classification, documentation or authorisation arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market usually affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance simultaneously. If the project is driven only by the question of which documents to submit, deficiencies or rework are likely in model coverage, evidence chain consistency, label claims and certificate ownership. AIMEILI recommends that companies plan this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, instead of preparing documentation on an ad hoc basis for each country.

Applicable Scenarios and Core Questions

Companies searching for information on how to localise labelling and instructions for use for medical device registration in the Philippines are usually not looking for a conceptual explanation. They want to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorised representative is required, why timelines become extended, and which issues could affect their launch plan. Behind this question there are usually several intertwined elements: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East or Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling/IFU, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use environment, mode of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or has IVD characteristics. Only then should the risk classification and submission pathway be determined. Once the pathway is wrong, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target-market project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely in a commercial contract only, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and IFU, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated domestic NMPA documentation without reorganising the evidence according to the target market pathway.
• Having too many model specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of a sales partnership, without clarifying regulatory responsibilities, certificate ownership and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFU.
• Confirm the responsibilities, fees, certificate ownership and exit mechanisms of the local agent or authorised representative.
• Establish a target-country gap assessment table identifying what needs additional testing, translation, notarisation or supplementary declarations.

AIMEILI's View

AIMEILI advises companies not to view target-market registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it according to national requirements, is usually faster, more stable and more conducive to subsequent changes and renewals than preparing supplementary documentation country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent is usually involved in registration communication, changes, renewals and post-market incident handling. Unclear responsibilities and rights can affect certificate ownership and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, model specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labelling and IFU, clinical evaluation, risk management, performance verification and quality system certificates in particular must maintain version consistency.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate ownership.
• Track translation, notarisation, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the product being submitted, or if the manufacturing address, model specifications and IFU version do not match the test reports, the company may be asked for supplementary explanations even if it has prepared a large volume of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificates item by item. This step appears basic, but it can significantly reduce the probability of deficiency letters, particularly for projects involving simultaneous submissions in multiple GHWP member states or across multiple product families.

Localisation Conversion and Agent Responsibilities

Target-market registration projects usually involve local agents, authorised representatives, importers or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate ownership and subsequent market stability.

Labelling, IFU and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall processes, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model extension, IFU update or agent replacement then occurs, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency in a single country; more importantly, it enables a company to build a replicable overseas compliance capability and reduce the cost of starting documentation from scratch each time it enters a new market.

Continued Reading

Previous: How should the technical file be organised for medical device registration in the Philippines?

Next: How should clinical evaluation documentation be prepared for medical device registration in the Philippines?

Recommended Reading

• How should registration documentation be prepared for medical device registration in Malaysia?
• How should product classification be determined for medical device registration in Malaysia?
• How should the technical file be organised for medical device registration in Malaysia?
• How should labelling and instructions for use be localised for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Return to the FAQ Centre | News and Insights | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Sourcing principle: Priority is given to official regulatory authorities, international organisations, standards bodies and public regulatory information; industry media and project experience are used only as supplementary references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.